公开(公告)号：US20190134277A1

公开(公告)日：2019-05-09

申请号：US16182307

申请日：2018-11-06

Applicant: Massachusetts Institute of Technology ,  Seattle Children's Hospital d/b/a Seattle Children's Research Institute

Inventor： Omid Veiseh ,  Robert S. Langer ,  Daniel G. Anderson ,  William Shain ,  Brian W. Hanak ,  Samuel R. Browd ,  Robert F. Hevner

IPC: A61L29/08 ,  A61L29/16

Abstract: Neurological implants whose surfaces have been chemically and covalently modified to impart beneficial properties to the neurological implants are described. The neurological implants possess improved biocompatibility compared to a corresponding neurological implant that lacks the chemical modification. Following implantation in a subject, the surface-modified neurological implants induce a lower-foreign body response, compared to a corresponding unmodified product.

公开(公告)号：US20190070108A1

公开(公告)日：2019-03-07

申请号：US16177687

申请日：2018-11-01

Applicant: Massachusetts Institute of Technology ,  The Brigham and Women's Hospital, Inc.

Inventor： Andrew Bellinger ,  Shiyi Zhang ,  Carlo Giovanni Traverso ,  Robert S. Langer ,  Stacy Mo ,  Tyler Grant ,  Mousa Jafari ,  Dean Liang Glettig ,  Angela DiCiccio ,  Lowell L. Wood, JR. ,  Philip A. Eckhoff

IPC: A61K9/00 ,  C08L33/14 ,  A61K47/69 ,  A61K47/58 ,  C08L33/08 ,  C08L33/02 ,  C08G83/00 ,  C08G63/08 ,  C08G18/73 ,  C08G18/42 ,  A61M31/00 ,  A61K47/42 ,  A61K47/40 ,  A61K47/34 ,  A61K47/32 ,  A61K47/10 ,  A61K31/7048 ,  A61K31/65 ,  A61K31/357 ,  A61K9/48

Abstract: Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.g., ingestion of a solution that induces rapid dissolution/degradation). In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance (e.g., a therapeutic agent), and, optionally, a linker. In some such embodiments, the linker may be configured to degrade such that the residence structure breaks apart and is released from the location internally of the subject after a predetermined amount of time.

公开(公告)号：US20190038808A1

公开(公告)日：2019-02-07

申请号：US16153139

申请日：2018-10-05

Applicant: Children's Medical Center Corporation ,  Massachusetts Institute of Technology

Inventor： Robert S. Langer ,  Rajiv Saigal ,  Yang Teng

IPC: A61L27/50 ,  A61L27/26 ,  A61K9/00 ,  A61L31/06 ,  A61L27/56 ,  A61L27/58 ,  A61L31/04 ,  A61L27/38 ,  A61L27/18 ,  A61L31/14 ,  A61L31/00 ,  A61F2/02 ,  A61F2/44 ,  A61L27/54 ,  A61L31/16 ,  C08L67/04

Abstract: Devices and methods for the treatment of open and closed wound spinal cord injuries are disclosed. For example, described herein are devices and methods for mitigating secondary injury to, and promoting recovery of, spinal cord primary injuries. More particularly, certain embodiments of the present invention are directed to polymeric mini-tubes that may be used for the treatment of spinal cord injuries. In addition, other embodiments are directed to polymeric “fill-in” bandages that may be used for the treatment of spinal cord injuries. For example, an erodible, or biodegradable, form of biocompatible polymer of the present invention is fabricated for surgical implantation into the site of the spinal cord injury.

公开(公告)号：US20190015650A1

公开(公告)日：2019-01-17

申请号：US16036712

申请日：2018-07-16

Applicant: Massachusetts Institute of Technology

Inventor： Ana Jaklenec ,  Kevin J. McHugh ,  Robert S. Langer

IPC: A61M37/00 ,  A61B5/00 ,  A61B90/90 ,  A61B50/30 ,  A61K9/00 ,  A61K49/00 ,  A61K8/02 ,  A61Q1/02 ,  A61K49/18

Abstract: Microneedle patches have been developed that can be used to deliver therapeutic, prophylactic, diagnostic agents and/or dyes to the skin. The microneedles encapsulate the agent(s) to be delivered. These are formed of a biodegradable polymer that dissolves upon insertion into skin or tissue, so that the microneedles break off from the substrate forming the patch, remaining in the skin/tissue at the site of insertion. The patches are used to create a tattoo or to deliver therapeutic, prophylactic or diagnostic agent in combination with a tattoo. In one embodiment, the microneedle patch contains both vaccine and dye pigments to administer vaccine and record such administration in one application of the microneedle patch.

公开(公告)号：US10179195B2

公开(公告)日：2019-01-15

申请号：US14182095

申请日：2014-02-17

Applicant: Massachusetts Institute of Technology

Inventor： Christopher J. Bettinger ,  Joost P. Bruggeman ,  Lino da Silva Ferreira ,  Jeffrey M. Karp ,  Robert S. Langer ,  Christiaan Nijst ,  Andreas Zumbuehl ,  Jason Burdick ,  Sonia J. Kim

IPC: C12N11/08 ,  C08J3/24 ,  C08K5/00 ,  C08L67/02 ,  A61L31/06 ,  A61L27/18 ,  A61L27/38 ,  A61L27/58 ,  C08G63/685 ,  A61K35/12 ,  A61K35/48 ,  A61K45/06 ,  A61L31/14

Abstract: The present inventions in various aspects provide elastic biodegradable polymers. In various embodiments, the polymers are formed by the reaction of a multifunctional alcohol or ether and a difunctional or higher order acid to form a pre-polymer, which is cross-linked to form the elastic biodegradable polymer. In preferred embodiments, the cross-linking is performed by functionalization of one or more OR groups on the pre-polymer backbone with vinyl, followed by photopolymerization to form the elastic biodegradable polymer composition or material. Preferably, acrylate is used to add one or more vinyls to the backbone of the pre-polymer to form an acrylated pre-polymer. In various embodiments, acrylated pre-polymers are co-polymerized with one or more acrylated co-polymers.

公开(公告)号：US20180360765A1

公开(公告)日：2018-12-20

申请号：US16108465

申请日：2018-08-22

Applicant: Massachusetts Institute of Technology ,  The Children's Medical Center Corporation

Inventor： Arturo J. Vegas ,  Joshua C. Doloff ,  Omid Veiseh ,  Minglin Ma ,  Robert S. Langer ,  Daniel G. Anderson

IPC: A61K9/50 ,  C08B37/00 ,  A61K35/39 ,  C12N5/00 ,  A61L29/08 ,  C12N5/071 ,  A61L33/08 ,  A61K9/00 ,  A61L31/10 ,  C08L5/04

Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

公开(公告)号：US10149635B2

公开(公告)日：2018-12-11

申请号：US15237405

申请日：2016-08-15

Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY

Inventor： Albert Joseph Swiston ,  Robert S. Langer ,  Tadd Bernard Hughes ,  Kerry Johnson ,  Carlo Giovanni Traverso

IPC: A61B5/00 ,  A61B5/07 ,  A61B5/0205 ,  A61B5/11 ,  A61B7/02 ,  A61B5/02 ,  A61B5/08 ,  A61B8/02

Abstract: Reliable, real-time heart and respiratory rates are key vital signs used in evaluating the physiological status in many clinical and non-clinical settings. Measuring these vital signs generally requires superficial attachment of physically or logistically obtrusive sensors to subjects that may result in skin irritation or adversely influence subject performance. Given the broad acceptance of ingestible electronics, the approach disclosed here enables vital sign monitoring internally from the gastrointestinal tract. The large animal (porcine) experiments and a robust processing disclosed herein demonstrate the feasibility of this approach. Implementing vital sign monitoring as a stand-alone technology or in conjunction with other ingestible devices has the capacity to significantly aid telemedicine, optimize performance monitoring of athletes, military service members, and first-responders, as well as provide a facile method for rapid clinical evaluation and triage.

公开(公告)号：US10086013B2

公开(公告)日：2018-10-02

申请号：US15340082

申请日：2016-11-01

Applicant: Massachusetts Institute of Technology

Inventor： Yizhou Dong ,  Kevin Thomas Love ,  Robert S. Langer ,  Daniel Griffith Anderson ,  Delai Chen ,  Yi Chen ,  Arturo Jose Vegas ,  Akinleye C. Alabi ,  Yunlong Zhang

IPC: A61K31/535 ,  A61K31/7105 ,  A61K31/711 ,  C07D241/08 ,  A61K47/22

Abstract: Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R′, R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein.

公开(公告)号：US20180036333A9

公开(公告)日：2018-02-08

申请号：US15340082

申请日：2016-11-01

Applicant: Massachusetts Institute of Technology

Inventor： Yizhou Dong ,  Kevin Thomas Love ,  Robert S. Langer ,  Daniel Griffith Anderson ,  Delai Chen ,  Yi Chen ,  Arturo Jose Vegas ,  Akinleye C. Alabi ,  Yunlong Zhang

IPC: A61K31/7105 ,  A61K47/22 ,  C07D241/08 ,  A61K31/711

CPC classification number: A61K31/7105 ,  A61K31/711 ,  A61K47/22 ,  A61K2121/00 ,  C07C229/12 ,  C07C229/22 ,  C07C229/24 ,  C07C229/26 ,  C07C229/36 ,  C07C237/08 ,  C07C237/12 ,  C07C271/22 ,  C07C279/14 ,  C07C323/58 ,  C07D207/16 ,  C07D209/20 ,  C07D209/24 ,  C07D233/64 ,  C07D241/08 ,  C07D265/32 ,  C07D403/06 ,  C07D413/06 ,  C07D487/04 ,  C07D487/06 ,  C12N15/87 ,  C12N15/88 ,  C12Q1/025 ,  G01N33/15

Abstract: Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R′, R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein.

公开(公告)号：US09867869B2

公开(公告)日：2018-01-16

申请号：US14652011

申请日：2013-12-12

Applicant: Massachusetts Institute of Technology ,  The Children's Medical Center Corporation

Inventor： Daniel G. Anderson ,  Hung-Chieh Chou ,  Michael J. Webber ,  Benjamin C. Tang ,  Yair Levi ,  Yunlong Zhang ,  Rosemary Lynn Kanasty ,  Arturo Jose Vegas ,  Robert S. Langer

IPC: A61K38/28 ,  A61K47/48 ,  G01N33/66 ,  G01N33/74

CPC classification number: A61K38/28 ,  A61K47/54 ,  A61K47/542 ,  A61K47/543 ,  A61K47/549 ,  A61K47/554 ,  G01N33/66 ,  G01N33/74 ,  G01N2333/62

Abstract: Compounds, compositions, and methods for “smart” delivery of a therapeutic, prophylactic or diagnostic agent, such as glucose-mediated delivery of insulin through glucose-sensing insulin derivatives, are provided. The insulin derivatives bind serum albumin or agglomerate in vivo. The insulin derivatives effectively dissociate to release insulin in a hyperglycemic condition, where the complexation of glucose to a glucose-sensing element alters properties of the insulin derivative leading to the dissociation. The compounds, compositions, and methods provide a delivery strategy for both self-regulated and long-term diabetes management.